mismatch repair deficiency

Showing 1 - 10 of 10

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma Trial in United States (MT-8421, Nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +10 more
  • Los Angeles, California
  • +4 more
Sep 5, 2023

Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency Trial in China

Not yet recruiting
  • Adenocarcinoma of the Stomach
  • +2 more
  • Hangzhou, Zhejiang, China
  • +7 more
Feb 7, 2023

Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma Trial in Houston

Active, not recruiting
  • Advanced Colorectal Carcinoma
  • +24 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 20, 2022

Gastric Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Pittsburgh (Tumor Infiltrating Lymphocytes (TIL), Fludarabine +

Recruiting
  • Gastric Cancer
  • +9 more
  • Tumor Infiltrating Lymphocytes (TIL)
  • Fludarabine + Cyclophosphamide combination
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 21, 2022

Solid Tumor, Microsatellite Instability, Mismatch Repair Deficiency Trial in Australia (APL-501)

Completed
  • Solid Tumor
  • +3 more
  • Camperdown, New South Wales, Australia
  • +4 more
May 5, 2022

NSCLC, Small Cell Lung Cancer, Urothelial Carcinoma Trial in United States (N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • N-803 + Pembrolizumab
  • +9 more
  • Anchorage, Alaska
  • +34 more
Apr 4, 2022

Cervical Cancer, Gastric Cancer, Stomach Cancer Trial in United States (INCAGN02390)

Completed
  • Cervical Cancer
  • +20 more
  • Los Angeles, California
  • +3 more
Nov 12, 2021

Cancer, Metastatic, Cancer, Cancer of Pancreas Trial in New York (Clinical Trial Matching)

Recruiting
  • Cancer, Metastatic
  • +42 more
  • Clinical Trial Matching
  • New York, New York
    Massive Bio, Inc
May 21, 2021

The mCRC pMMR/MSS or dMMR/MSI-H Status Received Palliative

Completed
  • Colorectal Cancer Metastatic
  • +2 more
    • Guangzhou, Guangdong, China
      Sun yat-sen university cancer center
    Jul 23, 2020